Pipeline
Endeavor BioMedicines’ Pipeline
Endeavor’s pipeline is currently focused on continued demonstration of therapeutic potential in fibrotic lung disease as well as human proof-of-concept data in human epidermal growth factor 3 (HER3)-positive tumors.
ENV-101
IPF
Hedgehog Inhibitor
ENV-101
PPF
Hedgehog Inhibitor
ENV-501
Oncology
Anti-HER3 Antibody-Drug Conjugate (ADC)
Phase 2a Trial of ENV-101 Successfully Completed
In January 2024, Endeavor BioMedicines announced successful completion of the Phase 2a clinical trial evaluating ENV-101 in patients with idiopathic pulmonary fibrosis (IPF).
